Eradicating Yaws: A Community Effort in the Congo Basin
A campaign targets yaws in the Congo Basin, aiming for a healthier future.
Earnest Njih Tabah, Alphonse Um Boock, Chefor Alain Djam, Gilius Axel Aloumba, Boua Bernard, Nzoyem Colin Tsago, Irine Ngani Nformi, Loic Douanla Pagning, Elisaberth Baran-A-Bidias, Christian Elvis Kouayep-Watat, Smith Afanji, Ebai George, Marielle Patty Ngassa, Bonaventure Savadogo, Serges Tchatchouang, Valerie Donkeng, Yves Thierry Barogui, Sara Eyangoh, Kingsley Bampoe Asiedu
― 6 min read
Table of Contents
- How Does it Spread?
- Why is it Important?
- Current Challenges
- New Hope for Yaws Eradication
- Strategy for Eradication
- Total Community Treatment (TCT)
- Targeted Treatment (TTT)
- Health System Approach
- Supportive Measures
- Testing the Plan
- Setting the Scene
- Confirming the Problem
- Developing a Community Treatment Model
- The Planning Phase
- Strategic Planning Meeting
- High-Level Advocacy
- Local Preparations
- The Campaign Begins
- Monitoring the Campaign
- Collecting Data
- Evaluating the Campaign
- Side Effects of Treatment
- Tracking Yaws Prevalence
- Lessons Learned
- Conclusion
- Original Source
Yaws is a skin disease caused by a type of bacteria called Treponema pallidum. It's mainly a problem for children under 15 years old, but it can affect anyone. It starts with rashes and sores on the skin that can spread easily from person to person. If left untreated, it can lead to more severe problems affecting bones and joints.
How Does it Spread?
Yaws spreads through direct contact between people. If someone has a sore, the fluid from that sore can pass on the disease to others. The risk goes up in crowded places where hygiene isn’t great. Imagine living in a packed place with a lot of dirt – not a fun environment!
Why is it Important?
Yaws is part of a group of diseases called Neglected Tropical Diseases (NTDs), which often don’t get the attention they deserve. It was a huge health problem in the 1950s, affecting over 46 countries. An effort back then, led by the World Health Organization (WHO) and UNICEF, got rid of most cases using a one-time injection of penicillin. They managed to treat about 300 million people! But once those campaigns ended, yaws made a comeback in some areas.
Current Challenges
After dropping significantly in numbers, yaws started reappearing in the late 1970s and early 2010s. The WHO saw this and took action, encouraging countries to start programs to control yaws again. But many governments didn’t follow through. Financial issues, political problems, and other health priorities got in the way.
New Hope for Yaws Eradication
Despite the setbacks, there have been some promising developments recently:
- A successful trial in Papua New Guinea showed that azithromycin, an oral antibiotic, works just as well as penicillin for treating yaws.
- India was officially declared yaws-free in 2016.
- New tests became available to quickly check for yaws and monitor if treatments were working.
- WHO set a goal to eradicate yaws by 2020, which was later extended to 2030.
Strategy for Eradication
In 2012, experts came up with a plan known as "The Morges Strategy" to tackle yaws. The strategy is built on four key points:
Total Community Treatment (TCT)
The idea behind TCT is simple: everyone in the community gets treated, whether they show symptoms or not. This is usually done in two or three rounds, spaced out over time.
Targeted Treatment (TTT)
If someone is diagnosed with yaws, their close contacts, like family and friends, also get treatment. This helps stop the spread right in its tracks.
Health System Approach
Local health workers will keep looking for new cases and providing ongoing treatment. They will also spread the word about yaws and how to deal with it.
Supportive Measures
Teams responsible for yaws eradication will help health facilities with the needed support and guidance throughout the process.
Testing the Plan
To see how this strategy would work in a real setting, tests were carried out in various locations like Lihir Island (PNG) and districts in Ghana, with good results. Ultimately, a significant large-scale effort was launched with 1.5 million people targeted in the Congo Basin across three countries.
Setting the Scene
The Congo Basin is made up of areas in Cameroon, Central African Republic, and Republic of Congo. It has a warm and humid climate, with many villages connected only by footpaths. Many communities there are isolated and have limited access to basic services like clean water, electricity, and health care. The region is also home to indigenous groups that rely on the forest for their survival, making them particularly vulnerable to yaws.
Confirming the Problem
Before launching their treatment campaign, health officials needed to confirm how many people had yaws in the targeted areas. They conducted surveys to identify active cases and assess the situation. The results showed a concerning prevalence of yaws, prompting urgent action.
Developing a Community Treatment Model
Given the unique challenges in the Congo Basin, a new model for treatment was created. This model combined experiences from different health programs, focusing on a short campaign duration. The latest plan was executed in three main steps: planning, execution, and evaluation.
The Planning Phase
During this phase, meetings were held to outline the strategy, raise awareness among high-level officials, and prepare at the community level.
Strategic Planning Meeting
Key players gathered to discuss roles and responsibilities. They agreed on the timeline and tools needed for the treatment campaign.
High-Level Advocacy
Officials reached out to governmental authorities to ensure support for the campaign and inspire community involvement.
Local Preparations
Health teams trained local volunteers, created awareness materials, and mobilized community members. They spread the word through local radio and door-to-door visits.
The Campaign Begins
After planning, the campaign officially kicked off, with local officials participating in launch events. Over the next few days, treatment teams went door to door, providing azithromycin to everyone over six months old.
Monitoring the Campaign
Supervision was crucial to ensure everything went smoothly. Several levels of oversight were established, with local health officials making sure all treatment and reporting were done correctly.
Collecting Data
During the campaign, health teams collected data on the number of people treated, any side effects, and potential new cases of skin diseases. At the end of each day, reports were made to monitor progress and address issues rapidly.
Evaluating the Campaign
After the treatment campaign ended, evaluations took place to analyze data and find out how successful the treatments were. Meetings were held at both local and national levels to assess performance and identify any areas for improvement.
Side Effects of Treatment
While most people had minor side effects like nausea and abdominal pain, the reporting of side effects was generally low. Vigilance in monitoring helped ensure that any adverse events were noted and managed properly.
Tracking Yaws Prevalence
After the treatment campaign, data was collected to see how effective the campaign was in reducing yaws cases. There was a significant decrease in the number of clinical cases, confirming the treatment’s success.
Lessons Learned
The efforts to eradicate yaws in the Congo Basin provided valuable lessons:
- Short campaigns are effective.
- Engaging the community is key.
- Proper planning is essential.
- Support from local authorities makes a difference.
- Continuous monitoring and evaluation help improve future efforts.
Conclusion
The fight against yaws in the Congo Basin has showcased what can be achieved with a well-organized plan, strong community involvement, and support from health authorities. While significant progress has been made, there is still work to do. It’s all about continuing to treat, monitor, and educate to ensure yaws does not return to wreak havoc on communities.
So, if you're ever wandering through the Congo Basin and happen upon a treatment team, consider yourself lucky! They're probably up to something quite heroic-trying to wipe out yaws and give folks a healthier future.
Title: The Morges Strategy for Yaws Eradication: the first largescale Total Community Treatment with azithromycin against yaws in the Congo-Basin, using a novel model.
Abstract: AbstractO_ST_ABSContext and JustificationC_ST_ABSYaws is targeted for eradication by 2030. Total Community Treatment with azithromycin (TCT), a major component of the eradication strategy, has witnessed only three pilots since 2012. We implemented the first large-scale TCT in the Congo-Basin of Central Africa using a novel model. MethodologyWe implemented a novel 3-phase TCT model in 17 health districts of the Congo-Basin, spanning 3 countries. Two rounds were implemented in Cameroon, and one round each in Central African Republic (CAR) and the Republic of Congo; targeting 1,530,014 people (144,934(9.5%) Pygmies and 1,304,410(90.5%) Bantus). TCT was followed by post-campaign active surveillance, treatment of yaws cases and their contacts. ResultsAll 17 health districts were confirmed for yaws endemicity. Overall, 1,456,691 (95.21%; 95%CI: 95.17%-95.24%) persons were treated in the first round of TCT, including 552,356/594411 (92.92%; 95%CI: 92.86%-92.99%) in Cameroon, 359,810/373,994 (96.21%; 95%CI: 96.15%-96.27%) in CAR, and 544,526/561,609 (96.96%; 95%CI: 96.91%-97.00%) in Congo. For the second round implemented only in Cameroon, 615,503/642,947 (95.73%; 95%CI: 95.68%-95.78%) were treated. There was a 3-percentage-point increase in therapeutic coverage between the first and second round (P-value
Authors: Earnest Njih Tabah, Alphonse Um Boock, Chefor Alain Djam, Gilius Axel Aloumba, Boua Bernard, Nzoyem Colin Tsago, Irine Ngani Nformi, Loic Douanla Pagning, Elisaberth Baran-A-Bidias, Christian Elvis Kouayep-Watat, Smith Afanji, Ebai George, Marielle Patty Ngassa, Bonaventure Savadogo, Serges Tchatchouang, Valerie Donkeng, Yves Thierry Barogui, Sara Eyangoh, Kingsley Bampoe Asiedu
Last Update: 2024-11-08 00:00:00
Language: English
Source URL: https://www.medrxiv.org/content/10.1101/2024.11.07.24316738
Source PDF: https://www.medrxiv.org/content/10.1101/2024.11.07.24316738.full.pdf
Licence: https://creativecommons.org/licenses/by/4.0/
Changes: This summary was created with assistance from AI and may have inaccuracies. For accurate information, please refer to the original source documents linked here.
Thank you to medrxiv for use of its open access interoperability.